Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Johnson & Johnson “should have known that the J&J Products contained harmful, deleterious, carcinogenic and inherently dangerous asbestos dust and fibers” and the products reportedly did not ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Sales across other products were only down 1%. In 2020 and 2021 (albeit to a lesser degree in 2021), Johnson and Johnson benefitted from some unique, one-time tax benefits. These benefits did not ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...

In 2021, Johnson & Johnson unveiled a plan to spin off its consumer products division to focus on pharmaceuticals and medical technology. The company completed the Kenvue spinoff to shareholders ...

The global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer ...